All lobbying filings

TARPLIN, DOWNS & YOUNG, LLC

Lobbying for NOVARTIS · Use innovative science and technology to discover & develop breakthrough treatments

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Lobbying activity 4

Budget/Appropriations

Federal budget issues

Health Issues

MINI Act, IRA, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies, EPIC Act, supply chain, drug pricing and drug discount programs in federal programs, international drug reference pricing

Medicare/Medicaid

bio pharmaceutical reimbursement issues, IRA

Trade (domestic/foreign)

tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.